Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Mar;29(1):137-9.
doi: 10.1177/0394632015599701. Epub 2015 Dec 17.

Dilated cardiomyopathy following use of xenadrine EFX

Graziano Riccioni  1 , Giuseppe Speziale  2 , Luca Scotti  3 , Valentina Bucciarelli  3 , Silvia Cappetti  4 , Giuseppe Nasso  2 , Sabina Gallina  5 , Tonino Bucciarelli  3
Affiliations
Case Reports

Dilated cardiomyopathy following use of xenadrine EFX

Graziano Riccioni et al. Int J Immunopathol Pharmacol. 2016 Mar.

Abstract

We describe a case of a 35-year-old man presented at the emergency room of our institution with acute onset of dyspnea and dizziness. He was a body builder and had been using Xenadrine EFX for weight loss reduction. The laboratory analyses were normal. A chest radiograph showed an enlarged cardiac silhouette with clear lung fields. Transtoracic two-dimensional color Doppler echocardiography revealed a diffuse hypokinesia with a marked decreased in systolic function and a high teledyastolic diameter. This case document the possible relation to use of Xenadrine EFX for weight loss and the recurrence of dilated cardiomyopathy.

Keywords: dilated cardiomyopathy; weight loss; xenadrine.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
ECG.
Figure 2.
Figure 2.
Transtoracic two-dimensional color Doppler echocardiography.
See this image and copyright information in PMC

References

    1. Haller CA, Benowitz NL, Jacob P., 3rd (2005) Hemodynamic effects of ephedra-free weight-loss supplements in humans. American Journal of Medicine 118: 998–1003. - PubMed
    1. Haller CA, Benowitz NL. (2000) Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New England Journal of Medicine 343:1833–1838. - PubMed
    1. Flanagan CM, Kaesberg JL, Mitchell ES, et al. (2010) Coronary artery aneurysm and thrombosis following chronic ephedra use. International Journal of Cardiology 139: 11–13. - PubMed
    1. Sachdeva R, Sivasankaran S, Fishman RF, et al. (2005) Coronary thrombosis related to use of Xenadrine RFA. Texas Heart Institute Journal 32: 74–77. - PMC - PubMed
    1. Samenuk D, Link MS, Homoud MK, et al. (2002) Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clinic Proceedings 77: 12–16. - PubMed

Substances

LinkOut - more resources